Mission

Innovation's mission is to revolutionize the resorbable implants and regenerative medicine. Our core values are commitment, quality, and innovation, all towards improving patient outcomes.

 

 

History

In the last two decades, there have been numerous attempts to develop bioresorbable fixation implants combined with regenerative medicine. Still, these devices have fallen short in providing the optimal degradation profile, and also they degrade to acidic by-products causing local inflammation and delayed tissue regeneration. The main focus of the SDIP Innovations is to revolutionize the regenerative medicine and resorbable implants market using a patented formulated composite. SDIP's material is unique with optimal degradation profile and no acidic/basic by-products to leave behind. Besides, the animal studies show our technology results in excellent bone integration and tissue regeneration.  SDIP was founded as a private company in 2018 and is a spin off from the university of Sydney in Australia. The company is rapidly growing thanks to the continuous supports from NSW Health Government in Australia and UCSF Rosenman Institute and QB3 incubator in San Francisco as well as other valuable partners.

 

 

 

Core Team

Dr Maryam Parviz           

Co-founder & Chief Executive Officer   

Dr Iman Manavitehrani

Founder & Chief Scientific Officer

 

   A/Prof Aaron Schindeler

   Academic Advisor

 Ben Wright

  Business Advisor 

Dr Brett Fritsch

 Clinical Advisor 

Warren Bingham

Commercialization Advisor